Region | Sample | Source | 155391G & 155391G/A | 155391A | OR |
P
|
---|
Guangdong | Healthy subjectsa
| TW | 743 | 697 | 1 | Â |
 | EBV-free tumor#
| TW | 24 | 15 | 0.67â€
| 0.257 |
 | NHL‡
| TB | 8 | 5 | 0.67â€
| 0.582 |
 | HL | TB | 7 | 3 | 0.46â€
| 0.345 |
 | Lymphoma (NHL + HL) | TB | 15 | 8 | 0.57â€
| 0.213 |
 | NPC | TB | 22 | 100 | 8.35˄
| <0.001 |
Shandong | Healthy subjectsa
| TW | 578 | 34 | 1 | Â |
 | EBVaGC | TB | 10 | 0 | 0â€
| 1.000 |
 | NPC | TB | 23 | 13 | Inf˅
| 0.042 |
-
NHL non-Hodgkin’s lymphoma, HL Hodgkin’s lymphoma, EBVaGC EBV-associated gastric carcinoma. Other abbreviations as in Tables 1 and 2
-
aHealthy subjects from the discovery and replication stages were combined
-
#EBV-free tumors included lung cancer, liver cancer, colorectal cancer, and pancreatic cancer, among others, which were not associated with EBV
-
‡NHL included Burkitt’s and NK/T-cell lymphomas
-
†The frequency of RPMS1 SNP G155391A in healthy subjects from the same region was considered as a reference, with Fisher’s exact test performed
-
Ë„Lymphoma was considered as a reference
-
Ë…EBVaGC was considered as a reference